Opus Point Partners’ AUM, History and Investments

5. Loxo Oncology Inc (NASDAQ:LOXO)

Loxo Oncology Inc (NASDAQ:LOXO) is another new position in Opus Point Partners’ equity portfolio. Between April and June, Opus Point Partners acquired 13,800 shares worth $1.11 million. Other investors bullish on Loxo Oncology Inc (NASDAQ:LOXO) include Dennis Purcell’s Aisling Capital, OrbiMed Advisors, and Phil Gross and Robert Atchinson’s Adage Capital Management.

Loxo Oncology Inc (NASDAQ:LOXO)’s stock has surged by over 130% since the beginning of the year, boosted at the beginning of June by an announcement of positive interim results from three cliniacl trials of larotrectinib for the treatment of tumors that harbor tropomyosin receptor kinase (TRK) fusions.